Background: Group 2 innate lymphoid cells (ILC2s) are major producers of the cytokines driving allergic asthma, and increased ILC2 numbers have been detected in blood and sputum of asthmatic patients. Asthma susceptibility has a strong genetic component, but the underlying mechanisms and whether asthma genetics affect ILC2 biology remain unclear.
Objective: We sought to study the ILC2 transcriptome and epigenome during airway inflammation (AI) to couple these to genes and genetic variants associated with asthma pathogenesis. Methods: Mice harboring a reporter for the key ILC2 transcription factor GATA-3 were subjected to IL-33-driven AI, and ILC2s were isolated from bronchoalveolar lavage fluid and mediastinal lymph nodes. Human ILC2s were purified from peripheral blood and activated in vitro. We used RNA sequencing, genome-wide identification of histone-3 lysine-4 dimethylation-marked chromatin, and computational approaches to study the ILC2 transcriptome and epigenome.
Results: Activated ILC2s in mice displayed a tissue-specific gene expression signature that emerged from remarkably similar epigenomes. We identified superenhancers implicated in controlling ILC2 identity and asthma-associated genes. More than 300 asthma-associated genetic polymorphisms identified in genome-wide association studies localized to H3K4Me2 1 gene regulatory elements in ILC2s. A refined set of candidate causal asthma-associated variants was uniquely enriched in ILC2, but not T H 2 cell, regulatory regions. Conclusions: ILC2s in AI use a flexible epigenome that couples adaptation to new microenvironments with functional plasticity. Importantly, we reveal strong correlations between gene regulatory mechanisms in ILC2s and the genetic basis of asthma, supporting a pathogenic role for ILC2s in patients with allergic asthma. (J Allergy Clin Immunol 2018;142:1793-807.)
Key words: Group 2 innate lymphoid cell, epigenetics, epigenome, asthma, airway inflammation, genome-wide association study, superenhancer, transcription factor, T H 2 cell, GATA -3 Allergic asthma is a chronic disorder characterized by reversible airflow limitation, bronchial hyperreactivity, increased mucus production, and airway inflammation (AI). 1 More than 50% of patients have allergic eosinophilic asthma mediated by excessive type 2 immune responses to inhaled allergens, including house dust mite (HDM). Enhanced activation of T H 2 cells and the type 2 cytokines they produce explain many hallmarks of allergic asthma: IL-4 induces class-switch recombination to allergen-specific IgE; IL-5 supports eosinophil differentiation, activation, and recruitment into the lungs; and IL-13 mediates bronchial hyperreactivity, mucus hypersecretion, and airway remodeling. 1 The recent identification of group 2 innate lymphoid cells (ILC2s) as major producers of type 2 cytokines has challenged the central role of T H 2 cells in asthma etiology. [1] [2] [3] ILCs do not express antigen-specific receptors but play key roles in inflammation, host defense, and tissue homeostasis. 3 Innate lymphoid cells (ILCs) are categorized based on selective cytokine production and their transcription factor (TF) requirements, which mirror those of their adaptive T-cell counterparts. 3, 4 Group 1 ILCs produce IFN-g and express the TF T-bet, and group 3 ILCs are able to produce IL-17/IL-22 and depend on retinoic acid-related orphan receptor gt. ILC2s parallel T H 2 cells in that their development and expression of type 2 cytokines is crucially dependent on GATA-3.
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When exposed to IL-25, IL-33, thymic stromal lymphopoietin, prostaglandin D 2 , or leukotrienes, ILC2s rapidly expand and secrete large amounts of IL-5, IL-13, and, under certain conditions, IL-4. 3, 6, 7 ILC2s are essential for protective immunity against helminths and drive AI mediated by various allergens, including papain, chitin, or Alternaria alternata spores. 3, 8 Also in HDM-driven AI, ILC2s are major producers of IL-5 and IL-13, but their induction depends on prior allergen sensitization and T-cell activation. 9, 10 Moreover, increased ILC2 numbers, type 2 cytokine production by ILC2s, or both in blood and sputum of asthmatic patients have been reported. [11] [12] [13] [14] [15] [16] Strong environmental and genetic components influence asthma susceptibility, persistence, and response to medication. Numerous genes have been associated with asthma through genome-wide association studies (GWASs), 17, 18 but these provide limited insight into the underlying mechanisms and cell types affected. Recent studies have also uncovered regions of differential DNA methylation associated with allergic inflammation, 19, 20 but the molecular underpinnings of asthma-associated genetic and epigenetic variation remain largely unclear. 17, 21 Epigenomic profiling is uniquely suited to study the molecular basis of cellular identity and disease-associating genetic or epigenetic variation. 17, 22, 23 Supporting this strategy is a recent study of human circulating memory T H 2 cells reporting epigenetic differences between asthmatic patients and healthy control subjects, as well as an enrichment of asthma-associated single nucleotide polymorphisms (SNPs) in gene regulatory elements (GREs) of T H 2 cells. 24 The epigenome of murine ILC2s from the lungs in the setting of helminth-induced inflammation 25, 26 or the small intestine 27 have recently been explored. However, an in-depth analysis of the epigenetic basis of ILC2 cellular identity and activation is still lacking, precluding a better understanding of environmental adaptation and plasticity in ILC2s driving AI. Moreover, human ILC2 biology has remained unexplored at the epigenetic level. As a consequence, it is currently unknown whether genetic variants implicated in human asthma affect gene regulatory processes in ILC2s. Here we addressed gene activation in ILC2s mediating AI in a genome-wide fashion using an epigenomic approach. We found that ILC2s activated in vivo by IL-33 in mice use an extensively primed epigenome that allows for rapid adaptation of the ILC2 gene expression program to different tissue microenvironments. Genes that safeguard ILC2 identity and effector function are controlled by superenhancer (SE) elements that are often bound by the TFs GATA-3 and growth factor-independent 1 transcriptional repressor (GFI1). Importantly, analysis of human peripheral blood-derived ILC2s showed that the majority of asthmaassociated genes could be linked to active or primed GREs in ILC2s, with more than 300 asthma-associated genetic variants, including candidate causal SNPs, residing in ILC2-specific GREs.
METHODS
A more detailed description of all methods can be found in the Methods section in this article's Online Repository at www.jacionline.org.
Mice and lymphocyte isolation
ILC2s were isolated from IL-33-treated GATIR mice (Gata3 YFP/YFP ; T.N.R. and H.J.F., manuscript in preparation). Human peripheral blood T H 2 cells and ILC2s were isolated and activated in vitro, as previously described. 24, 28 Experiments were approved by relevant ethical committees.
RNA sequencing and Chromatin immunoprecipitation using tagmentation (ChIPmentation)
RNA extraction and sequencing library preparation were described previously. 29, 30 ChIPmentation was performed, as previously described. Tagmented DNA was amplified and sequenced on a NextSeq 500 (Illumina, San Diego, Calif). Downstream analyses were performed with HOMER. 32 
Accession numbers
All sequencing data sets were deposited in the Gene Expression Omnibus (accession no. GSE98843).
RESULTS

Isolation of ILC2s driving AI by using Gata3 reporter mice
To isolate murine ILC2s, we used Gata3 YFP/YFP reporter mice harboring an IRES-YFP sequence knocked into the Gata3 locus (GATIR mice). GATA-3 protein levels or functions in IL-33/ scape at selected loci known to be essential for ILC2 function (Fig 3, B) or newly identified as harboring an active chromatin signature in ILC2s (Fig 3, C) . D, Metaprofile depicting average enrichment levels for all H3K4Me2 1 GREs associated with genes upregulated in MLN (left) or BAL fluid (right) ILC2s. Signal measured in a mock experiment (using an aspecific IgG) is shown in gray. E, Identification of differentially H3K4Me2-enriched regions (>2-fold change) between BAL fluid and MLN ILC2s in 2 independent experiments (each representing a pool of 5-6 mice). F and G, Gene expression levels (Fig 3, F) and H3K4Me2 landscapes (Fig 3, G) of the interferon signaling-induced genes Ifit1 and Mx1 in ILC2s.
selected genes from both groups. C, Normalized expression counts for Alox5 and eotaxin 2 (Ccl24) shown in a genome browser view. Genes are plotted at the top as black bars with an arrow, indicating the transcription start site and directionality; exons are indicated below. D, Molecular pathway enrichment (MSigDB) among genes upregulated in BAL fluid (blue bars) or MLN (red bars) ILC2s. FDR, False discovery rate. E, Gene expression levels of selected genes differentially expressed between BAL fluid and MLN ILC2s (mean 1 SEM values of n 5 2 pools of 5-6 mice). F, Ki67 mean fluorescence intensity in ILC2s isolated from BAL fluid or MLNs (mean 1 SEM values of n 5 3 groups of 3-6 mice). ***P < _ .001, Mann-Whitney U test. 
YFP
1 cells (Fig 1, A and B) . AI was induced by intranasal exposure to IL-33, resulting in robust accumulation of eosinophils, CD4
1 T cells, and ILC2s in bronchoalveolar lavage (BAL) fluid and lung-draining mediastinal lymph nodes (MLNs ; Fig 1, C) . Both BAL fluid and MLN ILC2 populations consisted predominantly of inducible costimulator (ICOS)
1 , killer cell lectin-like receptor G1 (KLRG1) 1 , CD25 1 activated effector cells with the capacity to produce IL-5, IL-13, or both (Fig 1, D, and see Fig E1, D) . Although surface marker profiles of BAL fluid and MLN ILC2 populations were similar, we did notice tissue-specific differences in levels of, for example, KLRG1, T1/ST2 (IL-33R), ICOS, and CD117 (Fig 1, D) . To obtain further insight into the molecular underpinnings of ILC2s driving IL-33-induced AI, we set out to characterize their transcriptome (by using RNA sequencing [RNA-Seq]) and epigenome (using histone-3 lysine-4 dimethylation [H3K4Me2] ChIPmentation; Fig 1, E) .
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Tissue microenvironments modulate ILC2 gene expression programs RNA-Seq revealed substantial gene expression differences between ILC2 counts from BAL fluid or MLNs (n 5 1201 genes, >2-fold difference, adjusted P < .05; Fig 2, A and B , and see Table E1 in this article's Online Repository at www.jacionline. org), with excellent purity and reproducibility between biological replicates (R 2 > 0.97; see Fig E2, A and B, in this article's Online Repository at www.jacionline.org). In agreement with our flow cytometric analysis, Klrg1 expression was higher in MLN ILC2s, whereas expression of Il1rl1 encoding T1/ST2 (IL-33R), Il2ra (CD25), and Kit (CD117) were upregulated in BAL fluid ILC2s (Fig 2, B-E ). Icos and Il7r (CD127) were expressed at similar levels, suggesting that ICOS protein levels are regulated differentially at the posttranscriptional level (see Table E1 ).
Compared with ILC2s from MLNs, BAL fluid ILC2s exhibited a more inflammatory phenotype expressing high levels of IL-33 receptor (Il1rl1) and cysteinyl leukotriene activation receptors (Cysltr1/2), proinflammatory cytokines (eg, Il9, Il21, Il5, and Il13), chemoattractants (eg, Ccl6, Ccl7, Ccl9, and eotaxin 2), and costimulatory receptors (eg, Gitr and Ox40; Fig 2, B-E) . Surprisingly, Ctla4 and Il10 expression was also markedly higher in BAL fluid ILC2s, hinting at a possible regulatory function of (a subset of) ILC2s specifically in the lungs (Fig 2, E) .
In addition to Klrg1, MLN ILC2s also expressed higher levels of Ox40l and MHC class II-like H2-O genes, suggesting MLN ILC2s are actively involved in cell-cell interactions with dendritic cells or T H 2 cells. [34] [35] [36] [37] [38] Interestingly, MLN ILC2s upregulated Nod1, a pattern recognition receptor that drives T H 2 polarization and has been implicated in asthma. 39 ,40 MLN ILC2s expressed high levels of Alox5, which encodes the 5-lipoxygenase enzyme involved in the production of leukotrienes, potent activators of ILC2s and allergic asthma. 41, 42 MLN ILC2s also expressed greater levels of the neuropeptide receptor gene Nmur1, which was recently implicated in promoting allergic inflammatory ILC2 responses through neuroimmune crosstalk (Fig 2, B-E) . 43 In line with these observations, confocal microscopy of IL-33-treated GATIR mice revealed differences in the ILC2 microenvironment in lungs (underneath the epithelium) and MLNs (near T and B cells; see Fig E2, C) .
We observed tissue-specific expression differences in metabolism-and survival/proliferation-associated pathways. Although BAL fluid ILC2s upregulated genes involved in the lipid response (eg, the free fatty acid receptor gene Ffar2) and cell survival (eg, Bcl2), MLN ILC2s showed enhanced glycolysis and cell division (Fig 2, B-E) . Upregulation of an aerobic glycolytic metabolic program is a hallmark of effector lymphocyte activation [44] [45] [46] and therefore is consistent with increased ILC2 proliferation in the MLN. This is further illustrated by upregulation of Mki67 encoding the Ki67 proliferation marker, which we validated using flow cytometry (Fig 2, F) . Nevertheless, the absolute increase in ILC2 cellularity was comparable for BAL fluid and MLN samples (Fig 1, C) , suggesting that ILC2 expansion in MLNs occurred later or with slower kinetics than local proliferation in the lung. Alternatively, ILC2s from the MLNs might be actively recruited to the lung.
Tissue-specific gene expression profiles in ILC2s arise from highly similar epigenomes
To assess whether the observed transcriptional differences were also reflected in epigenetic alterations, we profiled H3K4Me2 1 chromatin in ILC2s. H3K4Me2 accurately marks both active and primed GREs, providing a comprehensive catalogue of transcription-permissive chromatin. 47, 48 We used ChIPmentation, a genome-wide chromatin immunoprecipitation protocol adapted to low numbers of starting cells, 31 to analyze approximately 20,000 freshly isolated ILC2s (Fig 1,  E) . H3K4Me2 enrichments correlated with gene expression and showed high-quality signal/noise ratios (see the Methods section and Fig E3 in GREs (see Fig E4, A, in this article's Online Repository at www.jacionline.org). GRE distribution was identical between BAL fluid and MLN ILC2s, and as expected, signature ILC2 loci (eg, Bcl11b, Gata3, and the T H 2 locus) were embedded in active chromatin (Fig 3, A and B) . ChIPmentation also identified H3K4Me2 signatures at loci not previous implicated in ILC2 biology, such as the T-cell receptor g locus Cd320 (encoding the vitamin B12 receptor) and the vascular endothelial growth factor C (Vegfc) locus (Fig 3, C) .
Surprisingly, H3K4Me2 levels at GREs near differentially expressed genes were highly similar in BAL fluid and MLN ILC2s (Fig 3, D, and see Fig E4, B) . Unbiased genome-wide comparisons between the epigenomes of the 2 ILC2 populations across replicate experiments yielded very few reproducibly differentially enriched regions (n 5 43 of >27,000 GREs, >2-fold difference; Fig 3, E, and see Fig E4, C) . Only a single group of genes involved in interferon signaling displayed consistently greater H3K4Me2 enrichment and gene expression in BAL fluid ILC2s (Fig 3, F and G, and see Fig E4, D) . Thus tissue-specific gene expression profiles in ILC2s driving AI arise from highly similar epigenomes.
Extensive epigenetic priming of ILC2s in AI
ILCs provide a sentinel function as early responders to immunologic challenges 3 and would thus benefit from a broadly permissive epigenome that allows for rapid gene activation and functional plasticity. In patients with IL-33-driven AI, a substantial fraction (approximately 37%) of all H3K4Me2 1 GREs was associated with genes not or very lowly expressed (RPKM < 2). These GREs displayed lower average H3K4Me2 levels when compared with GREs linked to active genes (Fig 4, A) . Repressed genes associated with H3K4Me1/2 are considered primed for rapid activation on receiving an appropriate stimulus. 50, 51 Pathway analysis of primed genes in 1 GRE but expressed at very low levels (RPKM < 2). P values were determined by using a Wilcoxon rank-sum test; percentages indicate proportions of all GREs belonging to either category. B, Proportions of active, primed, or silent genes (as determined by using AI ILC2 H3K4Me2 and transcriptome data) belonging to previously defined 49 gene signatures of ILC2s (from the small intestine [SI]) or group 3 innate lymphoid cells (ILC3s). C and D, Gene expression levels (Fig 4, C) and H3K4Me2 landscapes (Fig 4, D) of the core group 1 innate lymphoid cell (ILC1) genes Ifng and Tbx21 in ILC2s (mean 1 SEM values of n 5 2 pools of 5-6 mice). The dashed line indicates the 2-RPKM cutoff used to define primed genes. E, Metaprofile depicting average GATA-3 or GFI1 enrichment levels at H3K4Me2 1 GREs associated with active or primed genes. F, Unbiased TF-binding motif search within active or primed GREs. For each TF, heat maps indicate its expression status in ILC2s (yellow, active; gray, primed) and motif enrichment scores (white-tored gradient of adjusted P values) for the 2 GRE subsets.
ILC2s revealed a significant overrepresentation of genes involved in cytokine and chemokine signaling in contrast to the many general housekeeping functions enriched among active genes (see Fig E5, A, in this article's Online Repository at www.jacionline.org). For example, we detected primed chromatin environments at loci linked to airway remodeling (see Fig  E5, B and C), including Bmp2, 52 Acvr1b (encoding the receptor for TGFb-family member activin A, an allergen-responsive cytokine with increased levels in asthmatic patients 53 ), the Cxcl3 chemokine cluster that induces smooth muscle cell migration and airway remodeling, 54 and Has3, encoding an enzyme involved in the synthesis of hyaluronan, a major extracellular matrix component that accumulates during asthma. 55 Primed genes in airway ILC2s also included many that were previously reported as specifically expressed in either ILC2s or group 3 ILCs isolated from the small intestine, such as the Rorc locus that encodes retinoic acid-related orphan receptor gt (Fig 4, B) . 49 Moreover, the key group 1 ILC genes Tbx21 and Ifng (encoding T-bet and IFN-g, respectively) were primed or expressed at low levels in ILC2s (Fig 4, C and D) . Together, these findings reveal extensive priming of GREs and hallmarks of functional plasticity in ILC2s during AI.
We next explored the molecular mechanisms underlying epigenetic priming in ILC2s. The TFs GATA-3 and GFI1 bind to thousands of GREs in ILC2s, 56, 57 often representing H3K4Me2 1 enhancers (see Fig E6 in this article's Online Repository at www.jacionline.org). Cobinding by both TFs was infrequent (<20% of binding sites), although more than 50% of their target genes were shared, suggesting coregulation using different GREs (see Fig E6, F) . Genes regulated by both TFs or only by GATA-3 were involved in various immune signaling pathways (eg, T H 2 cytokine expression), whereas genes specifically targeted by GFI1 displayed predominantly housekeeping functions (see Fig E6, G) . However, both factors bound with near-equal affinities to active and primed GREs (Fig 4, E) .
A more unbiased approach for investigating differential TF binding is to scan regions of interest for the presence of TF binding motifs. 32 We detected a strong enrichment of GATA-3 and GFI1 motifs in both categories of GREs, validating our approach (Fig 4, F) . Other TFs expressed in ILC2s potentially operating at both primed and active GREs included ETS, IRF, PRDM, and RUNX TFs, most of which have not been previously reported as ILC2 regulators. This group included the SMAD2/3 TFs that relay signals of the TGF-b pathway, which is known to enhance ILC2 function. 58 We also found several differentially enriched motifs, indicating that factors such as FOXP1, MYC, YY1, and signal transducer and activator of (Fig  5, D) and the primed Csf2 gene (encoding GM-CSF; Fig 5, E) . F, Proportion of ILC2 SEs bound by GATA-3, GFI1, or both. G, Example of an SE region bound by both GATA-3 (red rectangles) and GFI1 (blue rectangles). transcription 1 (activated in response to interferon signaling) and 6 (activated in response to IL-4/IL-13 signaling) are involved in creating and/or maintaining a chromatin state in ILC2s that facilitates gene activation. In contrast, transcription factor 12 (TCF12), hypoxia inducible factor 1 alpha (HIF1A), and CCCTC-binding factor (CTCF) might play a role in preventing full gene activation by maintaining a primed environment (Fig 4, F) .
SEs bound by GATA-3 and GFI1 control ILC2 identity
A special class of clustered GREs called superenhancers (SEs) regulate expression of cell identity genes and harbor diseaseassociated genetic variants. 59, 60 Because ILC2-associated SEs have not yet been described, we used our H3K4Me2 data sets to identify 762 ILC2 SEs according to previously defined criteria (see Table E2 in this article's Online Repository at www.jacionline.org). 59 ILC2 C6orf10  GSDMB  HLA-DPA1  PYHIN1  TSLP   GAB1  IL33  IL6R  LRRC32  PBX2   CDK2  DENND1B  GATA3  HLA-DQ  HLA-DR  IKZF4  IL13   IL18R1  IL1RL1  IL2RB  NOTCH4  ORMDL3  PDE4D  RAD50   RORA  SMAD3  USP38  WDR36   ALOX5   TNIP1 C6orf10  DENND1B  GAB1  USP38   GATA3  IKZF4  IL13  IL18R1  ALOX5   IL1RL1  IL2RB  LRRC32  NOTCH4   PDE4D  RAD50  RORA  SMAD3 superenhancers   IL5  IL13  DENND1B  BCL11B  GATA3  IL2RA  ETS1  RORA  SMAD3  BATF   BCL11B  GATA3  IL2RA  ETS1  IL7R  RORA  SMAD3  IL18R1  IRF1  TCF7 total: 308 SNPs False discovery rate; MAPK, mitogen-activated protein kinase; PDGFR, platelet-derived growth factor receptor; PI3K, phosphoinositide 3-kinase. D, SE identification based on H3K4Me2 profiles in human ILC2s. Selected SEs and their associated genes are indicated. E, Comparison of SE landscapes in nILC2s and aILC2s. Selected SE-associated genes are highlighted, and genome browser views are shown below (yellow shading, SE). F, Venn diagram depicting overlap between genes linked to asthma-associated SNPs (yellow) and nILC2-specific (red), aILC2-specific (blue), and shared (gray) GREs. Major asthma genes 17 are highlighted. G, Numbers and percentages of asthma GWAS SNPs overlapping with nILC2-or aILC2-specific GREs. *P 5 5.1e-25 and **P 5 2.8e-34, Fisher exact test. White markers denote random colocalization levels. Venn diagram depicts overlap between SNPs located within GREs in nILC2s or aILC2s. or T H 2 cells. **P 5 3.0e-38, Fisher exact test. White markers denote random colocalization levels. Venn diagram depicts overlap between SNPs located within GREs in ILC2s or T H 2 cells. B, Enrichment (shown as a heat map of P values from the Fisher exact test) of candidate causal SNPs 71 associated with various human disorders in ILC2-specific GREs, T H 2-specific GREs, and shared GREs. Nonimmune diseases (gray names) served as controls. C, SNP enrichment ratios (as defined by using the Fisher exact test) of selected human disease from Fig 8, B, for the 3 groups of GREs. Red dashed line indicates a significance threshold P value of .05. D, Genome browser views of loci in which asthma-associated GWAS SNPs coincide with ILC2 GREs. Colocalization occurs within distal (eg, GATA3 and ID2), intronic (eg, ZBTB16 and IKZF3), and promoter (eg, IL1RL1 and TLR1) GREs. Representative tracks from 2 donors are shown for naive (red, nILC2s) and activated (blue, aILC2s) ILC2s. SNPs are indicated by red lines, and regions of SNP-GRE colocalization are highlighted with yellow shading.
SEs were located in regions of open transcription-permissive chromatin, as expected (see Fig E7, A and B, in this article's Online Repository at www.jacionline.org). Top SEs were found at loci known to be critical for ILC2 biology, such as Rora, Il7r, Gata3, Bcl11b, and the T H 2 cytokine locus (Fig 5, A, and see Fig E7, C) . 59 Importantly, this analysis identified many SEs at loci encoding TFs that play important roles in T-cell biology but that have not been implicated in ILC2 function before, such as Ikzf1 (encoding Ikaros), Fli1, and Myb (Fig 5, A) . SE-associated genes also controlled key signaling pathways in ILC2s (Fig 5, B) .
Although most SE-associated genes resided in an active state (eg, Notch2; Fig 5, C and D) , a small proportion (approximately 13%) were primed, including the Csf2 locus encoding GM-CSF (Fig 5, E) . Because ILC2s from blood or nasal polyps are able to produce GM-CSF, 6 these observations are in line with tissuespecific gene expression programs in ILC2s emerging from a primed epigenome. Importantly, the majority (approximately 85%) of SEs were bound by GATA-3, GFI1, or both factors (Fig 5, F and G, and see Fig E6, B and C), implicating these proteins as central regulators of ILC2 SEs.
Human asthma susceptibility genes reside in an active or primed state in murine ILC2s
Whether ILC2s contribute to the genetic basis and molecular mechanisms underlying allergic asthma remains unclear. We found H3K4Me2
1 GREs in ILC2s near several active and primed genes associated with AI and asthma. In addition to classical type 2 immunity genes (eg, Gata3, Il1rl1, and Il5), these included (1) leukotriene metabolism genes, such as Alox5 and Cysltr1/2 61 ; (2) cyclic nucleotide second messenger metabolic genes, such as Gucy1a3 (guanylate cyclase 1 soluble subunit a3) and Calcrl, which encodes a receptor for the calcitonin gene-related peptide CGRP that acts as an inflammatory mediator in asthma 62 ; (3) the lipid inflammatory mediator prostaglandin E synthase (Ptges)
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; and (4) the serpin peptidase inhibitor clade E (Serpine2); (Fig 6, A and B) . 64 An unbiased analysis using a curated asthma-associated gene signature (Disease Ontology DOID:2841) 65 revealed highly significant associations of various epigenomic and transcriptomic ILC2 features with asthma (Fig 6, C) .
We next focused on genetic variants implicated in asthma susceptibility using a GWAS. We assigned asthma-associated SNPs (see the Methods section) 17, 66 to 665 putative target genes (see Table E3 in this article's Online Repository at www. jacionline.org). More than 90% of variants are located more than 5 kb away from promoter regions (Fig 6, D) and therefore likely modulate gene expression through enhancers or posttranscriptional mechanisms. Intersecting these asthma-associated genes with their mouse orthologues near H3K4Me2
1 GREs allowed us to link 494 (approximately 74%) asthma-associated genes to murine ILC2 GREs (within 1 Mb; median distance, 21.3kb), 280 of which were active and 214 of which represented primed genes in the IL-33-activated ILC2s (Fig 6, E) . Importantly, the expression profile of asthma-associated genes was similar for IL-33-activated ILC2s and ILC2s activated by chronic exposure to HDM allergen in vivo (Pearson R 5 0.85, see Fig E8 in this article's Online Repository at www.jacionline.org in this article's Online Repository at www.jacionline.org), indicating that epigenomic analysis of IL-33-activated ILC2s has relevance for allergen-driven AI.
Genetic basis of asthma is strongly linked to GREs in human ILC2s
To extend our findings to human cells, we profiled H3K4Me2 levels in naive ILC2s (nILC2s) freshly isolated from human peripheral blood 67 of healthy subjects and after in vitro activation with the physiologically relevant alarmins IL-25 and IL-33 (referred to as aILC2s; n 5 3-4; Fig 7, A, and see Fig E9, A, in this article's Online Repository at www.jacionline. org). 12, 17, 28, 67, 68 Activation of human nILC2s evoked substantial H3K4Me2 1 epigenome expansion around genes involved in lipid metabolism, cytokine/chemokine signaling, and asthma (Fig 7, B and C, and see Fig E9, B and C) . As a consequence, nILC2s and aILC2s displayed markedly different SE compositions (Fig 7, D and E). Although several hallmark ILC2 genes (eg, GATA3, RORA, and PTGDR2) were SE associated in both conditions, nILC2s acquired SEs at, for example, the IL5/IL13, BATF, and DENND1B loci (all implicated in AI or asthma 69, 70 ) on activation (Fig 7, D and E, and see Table E2 ). Integrating our human ILC2 epigenome data with GWAS findings increased the number of asthma-associated genes linked to H3K4Me2 1 ILC2 GREs to approximately 91% (605/665), including almost all major asthma loci (Fig 7, F) . The majority of these associations occurred with GREs marked with H3K4Me2 in both nILC2s and aILC2s (shared GREs) or only aILC2s (aILC2-specific GREs; Fig 7, F) . Epigenome comparison of mouse and human ILC2s revealed substantial conservation of SE composition, epigenetic signatures of plasticity, and permissive chromatin surrounding asthmaassociated genes (see Fig E10 in this article' s Online Repository at www.jacionline.org).
A more precise intersection of the 3405 known asthmaassociated GWAS SNPs with H3K4Me2 1 GREs revealed that more than 300 common genetic variants associated with asthma localized to active chromatin in ILC2s, a highly significant enrichment compared with random colocalization (P < 5.1e-25; Fig 7 , G, and see Table E5 in this article's Online Repository at www.jacionline.org). Many asthma variants were detected in GREs present in both nILC2s and aILC2s. Strikingly, a substantial number of SNPs (125/308) were found in regions that gain H3K4Me2 on activation (Fig 7, G) . In addition, up to 52% of differentially methylated DNA elements linked to asthma through an epigenome-wide association study (EWAS) 19, 20 resided in an ILC2 H3K4Me2
1 GREs (see Fig E9, D) . GREs in human T H 2 cells were previously shown to harbor asthma-associated SNPs. 24 To directly compare variant enrichment between ILC2s with T H 2 cells, we profiled H3K4Me2 levels in circulating memory T H 2 cells from 3 healthy subjects. We found a similar number of asthma-associated SNPs residing in T H 2 cell or ILC2 H3K4Me2
1 GREs (314 and 308, respectively; P < 3.0e-38; Fig 8, A) . Interestingly, similar proportions of SNPs localized to GREs shared between ILC2s and T H 2 cells as to cell type-specific GREs.
We next extended these findings by analyzing a comprehensive set of refined candidate causal variants associated with various human disorders (including asthma and allergy; n 5 236 SNPs on average per disease 71 ) while separating shared, ILC2-specific, and T H 2 cell-specific H3K4Me2 1 GREs. Polymorphisms linked to immune disorders were highly enriched, often irrespective of the subset of GREs (eg, rheumatoid arthritis; Fig 8, B) . 71 SNPs associated with non-immune-related disorders (eg, chronic kidney disease) did not show significant enrichment, underscoring the specificity of our approach. However, ILC2s and T H 2 cells showed surprising differences in their disease associations. For example, although candidate causal SNPs for asthma were uniquely enriched in ILC2-specific GREs, allergy-associated SNPs were predominantly enriched in T H 2-specific H3K4Me2 1 regions (Fig 8, B and C) .
Our approach directly coupled ILC2 H3K4Me2 1 GREs to asthma-associated SNPs present in numerous loci implicated in human asthma pathogenesis, including distal enhancer elements and promoters (Fig 8, D) . Most asthma-associated SNPs colocalized with H3K4Me2 1 regions present in both nILC2s and aILC2s or exclusively in aILC2s, including several genes not previously implicated in ILC2 biology (eg, IKZF3 and PLCL1 ; Fig 8, D) .
DISCUSSION
Studies in mouse models and samples from human asthmatic patients have implicated ILC2s as potential drivers of allergic asthma. 68 Here we studied the ILC2 epigenome to gain insight into tissue-specific functions, plasticity, and activation of ILC2s in AI, as well as to assess whether ILC2 biology can be linked to the genetic basis of asthma susceptibility.
Our combined transcriptome and epigenome analyses demonstrate that ILC2s exposed to different tissue microenvironments have different gene expression profiles while maintaining a virtually identical H3K4Me2 epigenome. Together with the observed widespread epigenetic priming of genes, these findings indicate that ILC2s use a permissive epigenome for rapid adaptation to new microenvironments and external signals. This concept of ''epigenetic flexibility'' explains how activated ILC2s achieve functional plasticity in response to specific cytokines or viral infections. 28, [72] [73] [74] Although a recent study reported chromatin accessibility at the T H 2 cytokine locus already in murine ILC2 precursors, 25 this might be different for human ILC2s: our experiments show substantial H3K4Me2 epigenome expansion and SE changes when naive human ILC2s are exposed to IL-25/IL-33, including SE establishment at the T H 2 cytokine locus.
Our gene expression analysis points to interesting functional differences between ILC2s from the lungs or draining lymph nodes in AI. In the MLNs ILC2s are highly proliferative and express genes involved in promoting a T H 2 response and leukotriene production. In contrast, BAL fluid ILC2s display a more inflammatory nature (eg, highly active IRF4/IL-9 axis 75 ), express chemotactic (eg, eotaxin 2) and costimulatory molecules, and show signs of plasticity. In addition, location appears to be linked to metabolic differences: MLN ILC2s displayed signs of enhanced glycolysis, whereas BAL fluid ILC2s upregulated lipid response genes. Differences in nutrient availability between the various microenvironments could force ILC2s to adjust their transcriptome accordingly. 45, 46 Surprisingly, we detected increased expression of the inhibitory genes Il10 and Ctla4 in BAL fluid ILC2s, suggesting that as inflammation progresses, a regulatory gene expression program emerges in (a subset of) ILC2s. Overall, these observations add to the concept of ILC2s as a phenotypically heterogeneous 76, 77 and plastic 28, [72] [73] [74] cell population. A limitation of our study is that IL-33-driven eosinophilic AI only partly recapitulates allergen-driven AI. Although in our hands chronic HDM allergen-driven AI generated too few ILC2s for epigenome analysis, expression of asthma-associated genes was similar in ILC2s generated by means of IL-33 or HDM induction, indicating that IL-33-activated ILC2s are relevant for allergen-driven AI. Therefore our epigenome and transcriptome maps provide a resource for discovering new pathways and proteins important for ILC2 function in general and in the context of AI. SE composition, epigenetic hallmarks of plasticity, and permissive chromatin landscapes surrounding asthma-associated genes were often conserved between activated murine and human ILC2s.
Previous work has suggested that noncoding disease variants function primarily by disrupting long-range gene regulation. 24, 78, 79 For the first time, our analysis of human ILC2s links the genetics underlying asthma pathogenesis to the ILC2 epigenome. Most asthma-associated genes reside near GREs active in ILC2s, which harbored more than 300 asthma GWAS SNPs. Similar enrichments were observed for T H 2 cells, but 50% of polymorphisms localized to cell type-specific H3K4Me2 1 regions. Strikingly, candidate causal asthma SNPs were uniquely enriched in ILC2-specific GREs. Such differential enrichment of disease-associated variants among T H 2 cells and ILC2s extended to other immune disorders and warrants further exploration in subsequent studies.
The current study prioritizes a highly specific part of the ILC2 epigenome that consists of 127 enhancers and promoters (0.77% of all combined human ILC2 GREs, see Table E5 ) for functional follow-up studies. Associated with these regulatory regions are genes with well-known roles in (allergic) AI and ILC2 function (eg, IL13, IL1RL1, and GATA3) but also many genes not previously associated with ILC2s (eg, ORMDL3 and IKZF1). A plausible scenario at play here is that genetic or epigenetic variants perturb TF binding to these GREs, resulting in deregulated gene expression and ultimately phenotypic changes in ILC2s.
In conclusion, our study directs a substantial proportion of the genetic basis of asthma to the ILC2 epigenome, further strengthening a role for ILC2s in asthma pathogenesis. Moreover, because recently developed epigenetic drugs (eg, BET bromodomain inhibitors 80 ) primarily inhibit SE activity, the ILC2-associated SEs identified here could provide novel therapeutic angles to control ILC2-mediated AI.
